XML 36 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition (Notes)
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
REVENUE
The Company disaggregates revenue from contracts with customers by product, service, timing of revenue recognition, and geography. A summary by the Company’s reportable segments follows:
For the three month ended
March 31, 2020
U.S. Operations
 
Swiss Operations
 
Western European Operations
 
Chinese Operations
 
Other Operations
 
Total
Product Revenue
$
177,436

 
$
24,276

 
$
105,877

 
$
90,321

 
$
91,424

 
$
489,334

Service Revenue:
 
 
 
 
 
 
 
 
 
 
 
Point in time
50,234

 
5,557

 
31,391

 
7,106

 
25,676

 
119,964

Over time
13,739

 
2,064

 
16,057

 
3,172

 
4,832

 
39,864

Total
$
241,409

 
$
31,897

 
$
153,325

 
$
100,599

 
$
121,932

 
$
649,162

For the three month ended
March 31, 2019
U.S. Operations
 
Swiss Operations
 
Western European Operations
 
Chinese Operations
 
Other Operations
 
Total
Product Revenue
$
174,256

 
$
26,665

 
$
116,555

 
$
111,416

 
$
95,455

 
$
524,347

Service Revenue:
 
 
 
 
 
 
 
 
 
 
 
Point in time
49,651

 
4,951

 
33,939

 
7,704

 
24,018

 
120,263

Over time
10,743

 
1,961

 
15,412

 
2,603

 
4,123

 
34,842

Total
$
234,650

 
$
33,577

 
$
165,906

 
$
121,723

 
$
123,596

 
$
679,452

A breakdown of net sales to external customers by geographic customer destination for the three months ended March 31 follows:
 
2020
 
2019
Americas
$
264,824

 
$
258,631

Europe
194,828

 
209,555

Asia / Rest of World
189,510

 
211,266

Total
$
649,162

 
$
679,452


The Company's global revenue mix by product category is laboratory (55% of sales), industrial (39% of sales) and retail (6% of sales). The Company's product revenue by reportable segment is proportionately similar to the Company's global mix except the Company's Swiss Operations is largely comprised of laboratory products, while the Company's Chinese Operations has a slightly higher percentage of industrial products. A breakdown of the Company’s sales by product category for the three months ended March 31 follows:
 
2020
 
2019
Laboratory
$
357,091

 
$
359,732

Industrial
252,355

 
271,320

Retail
39,716

 
48,400

Total
$
649,162

 
$
679,452



The payment terms in the Company’s contracts with customers do not exceed one year and therefore contracts do not contain a significant financing component. In most cases, after appropriate credit evaluations, payments are due in arrears and are recognized as receivables. Unbilled revenue is recorded when performance obligations have been satisfied, but not yet billed to the customer. Unbilled
revenue as of March 31, 2020 and December 31, 2019 was $22.3 million and $17.4 million respectively, and is included within accounts receivable. Deferred revenue and customer prepayments are recorded when cash payments are received or due in advance of the performance obligation being satisfied. Deferred revenue primarily includes prepaid service contracts, as well as deferred installation.

Changes in the components of deferred revenue and customer prepayments during the periods ended March 31, 2020 and 2019 are as follows:
 
2020
 
2019
Beginning balances as of January 1
$
122,489

 
$
105,381

Customer pre-payments/deferred revenue
145,168

 
167,599

Revenue recognized
(120,291
)
 
(144,303
)
Foreign currency translation
(2,530
)
 
285

Ending balance as of March 31
$
144,836

 
$
128,962



The Company generally expenses sales commissions when incurred because the contract period is one year or less. These costs are recorded within selling, general, and administrative expenses. The Company has not disclosed the value of unsatisfied performance obligations other than customer pre-payments and deferred revenue above as most contracts have an expected length of one year or less and amounts greater than one year are immaterial.